# QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

> **NCT01147965** · PHASE1,PHASE2 · COMPLETED · sponsor: **NantCell, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Colorectal Cancer
- Lung Cancer
- Breast Cancer
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Ad5 CEA Vaccine

## Key facts

- **NCT ID:** NCT01147965
- **Lead sponsor:** NantCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-16
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147965, "QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01147965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*